본문 바로가기
KERD
논문KCI 등재

Drug-induced Hyperthermic Syndromes in Psychiatry

Stanley N. Caroff|Charles B. Watson|Henry Rosenberg
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2021.02|Clinical Psychopharmacology and Neuroscience|제19권 제1호|pp. 1-11|DOI https://doi.org/10.9758/cpn.2021.19.1.1

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Antipsychotic agentsNeuroleptic malignant syndromeSerotonin syndromeMalignant hyperthermiaInduced hyperthermiaSubstance use disorders.

초록

Hyperthermia, or extreme elevations in body temperature, can be life-threatening and may be caused by prescription drugs or illegal substances acting at a number of different levels of the neuraxis. Several psychotropic drug classes and combinations have been associated with a classic clinical syndrome of hyperthermia, skeletal muscle hypermetabolism, rigidity or rhabdomyolysis, autonomic dysfunction and altered mental status ranging from catatonic stupor to coma. It is critical for clinicians to have a high index of suspicion for these relatively uncommon drug-induced adverse effects and to become familiar with their management to prevent serious morbidity and mortality. Although these syndromes look alike, they are triggered by quite different mechanisms, and apart from the need to withdraw or restore potential triggering drugs and provide intensive medical care, specific treatments may vary. Clinical similarities have led to theoretical speculations about common mechanisms and shared genetic predispositions underlying these syndromes, suggesting that there may be a common “thermic stress syndrome” triggered in humans and animal models by a variety of pharmacological or environmental challenges.

Abstract

Hyperthermia, or extreme elevations in body temperature, can be life-threatening and may be caused by prescription drugs or illegal substances acting at a number of different levels of the neuraxis. Several psychotropic drug classes and combinations have been associated with a classic clinical syndrome of hyperthermia, skeletal muscle hypermetabolism, rigidity or rhabdomyolysis, autonomic dysfunction and altered mental status ranging from catatonic stupor to coma. It is critical for clinicians to have a high index of suspicion for these relatively uncommon drug-induced adverse effects and to become familiar with their management to prevent serious morbidity and mortality. Although these syndromes look alike, they are triggered by quite different mechanisms, and apart from the need to withdraw or restore potential triggering drugs and provide intensive medical care, specific treatments may vary. Clinical similarities have led to theoretical speculations about common mechanisms and shared genetic predispositions underlying these syndromes, suggesting that there may be a common “thermic stress syndrome” triggered in humans and animal models by a variety of pharmacological or environmental challenges.

참고문헌 (70)

  1. Knochel JP, "Clinical disorders of fluid and electrolyte metabolism" (1994), McGraw-Hill
  2. Clark WG, "Drug-related heatstroke", Pharmacol Ther, 26, pp.345~388 (1984)
  3. Hayes BD, "Drug-induced hyperthermic syndromes: part I. Hyperthermia in overdose", Emerg Med Clin North Am, 31, pp.1019~1033 (2013)
  4. McAllen KJ, "Adverse drug reactions resulting in hyperthermia in the intensive care unit", Crit Care Med, 38(6 Suppl), pp.S244~S252 (2010)
  5. Rusyniak DE, "Toxin-induced hyperthermic syndromes", Med Clin North Am, 89, pp.1277~1296 (2005)
  6. Caroff SN, "Neuroleptic malignant syndrome and related conditions", pp.93~120 (2003), American Psychiatric Publishing, Inc
  7. Zhao X, "Hypothesis : exertional heat stroke-induced myopathy and genetically inherited malignant hyperthermia represent the same disorder, the human stress syndrome", Cell Biochem Biophys, 70, pp.1325~1329 (2014)
  8. Meyers EF, "Thermic stress syndrome", JAMA, 247, pp.2098~2099 (1982)
  9. Breed D, "Conserving wildlife in a changing world : understanding capture myopathy-a malignant outcome of stress during capture and translocation", Conserv Physiol, 7, pp.coz027~ (2019)
  10. Riazi S, "Updated guide for the management of malignant hyperthermia", Can J Anaesth, 65, pp.709~721 (2018)
  11. Rosenberg H, "Malignant hyperthermia : a review", Orphanet J Rare Dis, 10, pp.93~ (2015)
  12. Larach MG, "A clinical grading scale to predict malignant hyperthermia susceptibility", Anesthesiology, 80, pp.771~779 (1994)
  13. Caroff SN, "Neuroleptic malignant syndrome", Med Clin North Am, 77, pp.185~202 (1993)
  14. Strawn JR, "Neuroleptic malignant syndrome", Am J Psychiatry, 164, pp.870~876 (2007)
  15. Lao KSJ, "Antipsychotics and risk of neuroleptic malignant syndrome : a population-based cohort and case-crossover study", CNS Drugs, 34, pp.1165~1175 (2020)
  16. Caroff SN, "Neuroleptic malignant syndrome in the perioperative setting", Am J Anesthesiol, 28, pp.387~393 (2001)
  17. Stanley N. Caroff, "Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors", Clinical Psychopharmacology and Neuroscience, 18(2), pp.322~326 (2020), 대한정신약물학회[DOI]
  18. Su YP, "Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome", Acta Psychiatr Scand, 130, pp.52~60 (2014)
  19. Schumacher LT, "Agitation management in pediatric males with anti-N-methyl-D-aspartate receptor encephalitis", J Child Adolesc Psychopharmacol, 26, pp.939~943 (2016)
  20. Caroff SN, "Phenomenology and management of encephalitis", J Neuropsychiatry Clin Neurosci, 31, pp.399~ (2019)
  21. Gurrera RJ, "An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method", J Clin Psychiatry, 72, pp.1222~1228 (2011)
  22. Gurrera RJ, "A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome", J Clin Psychopharmacol, 37, pp.67~71 (2017)
  23. Nisijima K, "Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome", Neuropsychiatr Dis Treat, 9, pp.853~859 (2013)
  24. Masi G, "Massive asymptomatic creatine kinase elevation in youth during antipsychotic drug treatment : case reports and critical review of the literature", J Child Adolesc Psychopharmacol, 24, pp.536~542 (2014)
  25. Mann SC, "Neuroleptic Malignant Syndrome and Related Conditions", pp.45~74 (2003), American Psychiatric Publishing, Inc
  26. Caroff SN, "Neuroleptic malignant syndrome and related conditions", pp.1~44 (2003), American Psychiatric Publishing, Inc
  27. Huddleston DE, "Movement disorder emergencies: diagnosis and treatment", pp.29~42 (2013), Humana Press
  28. Martino G, "Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of Parkinsonism and of neuroleptic malignant syndrome", Medicine(Baltimore), 94, pp.e649~ (2015)
  29. Kaasinen V, "Akinetic crisis in Parkinson’s disease is associated with a severe loss of striatal dopamine transporter function : a report of two cases", Case Rep Neurol, 6, pp.275~280 (2014)
  30. Fujioka S, "Hospital-based study on emergency admission of patients with Parkinson’s disease", eNeurologicalSci, 4, pp.19~21 (2016)
  31. Alty J, "What to do when people with Parkinson’s disease cannot take their usual oral medications", Pract Neurol, 16, pp.122~128 (2016)
  32. Artusi CA, "Parkinsonism-hyperpyrexia syndrome and deep brain stimulation", J Neurol, 262, pp.2780~2782 (2015)
  33. Caroff SN, "Parkinsonism-hyperthermia syndrome and deep brain stimulation", Can J Anaesth, 64, pp.675~676 (2017)
  34. Baldo BA, "The anaesthetist, opioid analgesic drugs, and serotonin toxicity : a mechanistic and clinical review", Br J Anaesth, 124, pp.44~62 (2020)
  35. Abadie D, "Serotonin syndrome : analysis of cases registered in the French pharmacovigilance database", J Clin Psychopharmacol, 35, pp.382~388 (2015)
  36. Meltem Çobanoğulları Direk, "Serotonin Syndrome after Clomipramine Overdose in a Child", Clinical Psychopharmacology and Neuroscience, 14(4), pp.388~390 (2016), 대한정신약물학회
  37. Mafdy N. Basta, "Postoperative Serotonin Syndrome Following Methylene Blue Administration for Vasoplegia After Cardiac Surgery: A Case Report and Review of the Literature", Seminars in Cardiothoracic and Vascular Anesthesia, 25(1), pp.51~56 (2021), SAGE Publications[DOI]
  38. Milo Gatti, "Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic", pharmacodynamic analysis, 2021, pp.77(2), 233~239[DOI]
  39. Orlova Y, "Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome", JAMA Neurol, 75, pp.566~572 (2018)
  40. Francescangeli J, "The serotonin syndrome : from molecular mechanisms to clinical practice", Int J Mol Sci, 20, pp.2288~ (2019)
  41. Dunkley EJ, "The hunter serotonin toxicity criteria : simple and accurate diagnostic decision rules for serotonin toxicity", QJM, 96, pp.635~642 (2003)
  42. Radomski JW, "An exploratory approach to the serotonin syndrome : an update of clinical phenomenology and revised diagnostic criteria", Med Hypotheses, 55, pp.218~224 (2000)
  43. Sternbach H, "The serotonin syndrome", Am J Psychiatry, 148, pp.705~713 (1991)
  44. Boyer EW, "The serotonin syndrome", N Engl J Med, 352, pp.1112~1120 (2005)
  45. Nguyen H, "An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System", J Clin Pharm Ther, 44, pp.327~334 (2019)
  46. Coffey RJ, "Abrupt withdrawal from intrathecal baclofen : recognition and management of a potentially life-threatening syndrome", Arch Phys Med Rehabil, 83, pp.735~741 (2002)
  47. Doyle AJ, "N-methyl-3, 4-methylendioxymethamphetamine(MDMA)-related coagulopathy and rhabdomyolysis : a case series and literature review", Res Pract Thromb Haemost, 4, pp.829~834 (2020)
  48. Armenian P, "Multiple MDMA(Ecstasy)overdoses at a rave event : a case series", J Intensive Care Med, 28, pp.252~258 (2013)
  49. Grunau BE, "Dantrolene in the treatment of MDMA-related hyperpyrexia : a systematic review", CJEM, 12, pp.435~442 (2010)
  50. Russell T, "Ecstacyinduced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene", Anaesthesia, 67, pp.1021~1024 (2012)
  51. Fiege M, "Induction of malignant hyperthermia in susceptible swine by 3, 4-methylenedioxymethamphetamine("ecstasy")", Anesthesiology, 99, pp.1132~1136 (2003)
  52. Watson JD, "Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place?", Anaesthesia, 48, pp.1057~1060 (1993)
  53. Baldridge EB, "Phencyclidine", Emerg Med Clin North Am, 8, pp.541~550 (1990)
  54. Armen R, "Phencyclidine-induced malignant hyperthermia causing submassive liver necrosis", Am J Med, 77, pp.167~172 (1984)
  55. Smith KM, "Club drugs : methyl-enedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate", Am J Health Syst Pharm, 59, pp.1067~1076 (2002)
  56. Akmal M, "Rhabdomyolysis with and without acute renal failure in patients with phencyclidine intoxication", Am J Nephrol, 1, pp.91~96 (1981)
  57. Leonard JB, "Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016", J Psychopharmacol, 32, pp.1286~1294 (2018)
  58. Rosenberg J, "Hyperthermia associated with drug intoxication", Crit Care Med, 14, pp.964~969 (1986)
  59. Zawilska JB, "NBOMes-highly potent and toxic alternatives of LSD", Front Neurosci, 14, pp.78~ (2020)
  60. ethanamine (25I-NBOME): A Harmful Hallucinogen Review, "Journal of Analytical Toxicology", 2021, 947~956, pp.Oxford University Press (OUP), 10.1093[DOI]
  61. López-Giménez JF, "Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways", Curr Top Behav Neurosci, 36, pp.45~73 (2018)
  62. Candy JM, "Salicylate toxicity masquerading as malignant hyperthermia", Paediatr Anaesth, 8, pp.421~423 (1998)
  63. Kamour A, "Increasing frequency of severe clinical toxicity after use of 2, 4-dinitrophenol in the UK : a report from the National Poisons Information Service", Emerg Med J, 32, pp.383~386 (2015)
  64. Sousa D, "Diet aid or aid to die : an update on 2, 4-dinitrophenol(2, 4-DNP)use as a weight-loss product", Arch Toxicol, 94, pp.1071~1083 (2020)
  65. Kopec KT, "Role of dantrolene in dinitrophenol (DNP) overdose: a continuing question?", Am J Emerg Med, 37, pp.1216~ (2019)
  66. Van Schoor J, "Dantrolene is not the answer to 2, 4-dinitrophenol poisoning : more heated debate", BMJ Case Rep, 11, pp.e225323~ (2018)
  67. Torline RL, "Extreme hyperpyrexia associated with central anticholinergic syndrome", Anesthesiology, 76, pp.470~471 (1992)
  68. Mann SC, "Psychotropic drugs, summer heat and humidity, and hyperpyrexia : a danger restated", Am J Psychiatry, 135, pp.1097~1100 (1978)
  69. Shader RI, "Uses and toxicity of belladonna alkaloids and synthetic anticholinergics", Semin Psychiatry, 3, pp.449~476 (1971)
  70. Greenblatt DJ, "Drug therapy. Anticholinergics", N Engl J Med, 288, pp.1215~1219 (1973)

이 간행물의 다른 논문 (20건)

Biomarkers of Major Depressive Disorder: Knowing is Half the BattleSahil Malik, Ravinder Singh, Govind Arora, Akriti Dangol, Sanjay Goyalpp. 12-25Second-to-Fourth Digit Ratio (2D:4D) in Psychiatric Disorders: A Systematic Review of Case-control StudiesMaria Salvina Signorelli, Laura Fusar-Poli, Eugenio Aguglia, Alessandro Rodolico, Serena Sturiale, Bianca Carotenuto, Antimo Natale, Davide Arillotta, Spyridon Siafispp. 26-45Possible Modulatory Role of ARC Gene Variants in Mood DisordersConcetta Crisafulli, Marco Calabrò, Laura Mandelli, Ashwin Patkar, Prakash Masand, Chi Un Pae, Daniel Souery, Julien Mendlewicz, Sheng Min Wang, Alessandro Serretti, Changsu Han, Soo-Jung Leepp. 46-52Selective Serotonin Reuptake-Inhibitors for Symptom-Based Treatment of Borderline Personality Disorders in Older Adults: An International Delphi StudySebastiaan van Alphen, Julie Schulkens, Nina Bergs, Theo Ingenhoven, Erlene Rosowsky, Sjacko Sobczakpp. 53-62Association between Uncinate Fasciculus Integrity and Agoraphobia Symptoms in Female Patients with Panic Disorder이상혁, 원은수, Sung Eun Kim, Minji Bangpp. 63-72
원문 보기